Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
Dr. Robert Grant writes in the the Huffington Post about ending HIV transmission using the successful strategies of prenatal HIV care.
At the World Conference of Science Journalists, Dr. Shinya Yamanaka stressed that basic science research is essential for preparing the way for applications that will result in cures.
Vice documents Dr. Robert Grant's ground-breaking work on PrEP (pre-exposure prophylaxis), which has provided hope for ending the spread of HIV.
CRISPR, a powerful gene-editing tool, is the biggest game changer to hit biology since PCR. Dr. Bruce Conklin was an early adopter of the tecnology and is on the front lines of CRISPR research, using genome editing to study DNA mutations in heart disease.
Dr. Deepak Srivastava discusses the intricacies of cardiac surgery in an article about new technology that helps surgeons to navigate patients' hearts using 3-D imaging.
Blocking a specific protein with a little-known, experimental drug restored balance in the immune systems of lab mice, preventing them from developing multiple sclerosis, researchers at San Francisco's Gladstone Institutes found.
Researchers from the Gladstone Institutes have discovered that astrocytes - typically thought of as "helper" cells in the brain - are involved in forgetting, and too many of these cells may contribute to Alzheimer's disease. The researchers are now working to repurpose old drugs used for Parkinson's disease and epilepsy to use as new therapies to treat memory loss in Alzheimer's.
Gladstone Institutes postdoctoral fellow Casey Gifford, PhD, was awarded the Damon Runyon Cancer Research Foundation Fellowship to study DNA-binding proteins in order to understand how a disruption in the expression of these proteins can lead to cancer.
The antiretroviral drug Truvada is most effective at reducing the risk of infection when taken daily. But used before and after sex, as directed, PReP also significantly lessened the risk of HIV transmission.
Scientists have long thought that HIV's tendency to lay dormant within a person for 10 years or more was due to the behavior of the cells it infects or an error in the disease’s programming, but new evidence suggests that this inactivity may be an evolutionary strategy to help the virus to survive and spread.